DGAP-News

MOLOGEN AG: All key milestones achieved in 2015

DGAP-News: MOLOGEN AG / Key word(s): Final Results
MOLOGEN AG: All key milestones achieved in 2015

22.03.2016 / 07:11
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE N 6 / 2016 of 03/22/2016

MOLOGEN AG: All key milestones achieved in 2015

- Successful further development of the product pipeline with conclusion
of the patient enrollment for the IMPULSE study and the first phase of
the TEACH study

- Increase in R&D expenses due to study progress

- Successful capital increase with gross proceeds of EUR28.3 million

- Changes in the Executive Board

- Confident forecast for 2016

Berlin, 22 March 2016 - In financial year 2015, the biotechnology company
MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard:
MGN) achieved all key objectives and developed its product pipeline as
planned. The company focused on continuing the three clinical studies
involving the lead drug candidate lefitolimod (MGN1703). Patient enrollment
was completed as planned for the randomized IMPULSE study (indication small
cell lung cancer) and the TEACH study (indication HIV), which the company
has been carrying out jointly with Aarhus University Hospital since the
second quarter of 2015. Substantial progress was also made in patient
enrollment for the phase III IMPALA pivotal study (indication colorectal
cancer). The capital increase of EUR28.3 million, which took place in April
2015, was used primarily to fund the research and development program, for
the lead product lefitolimod (MGN1703) in particular. The Executive Board
expects that the clinical studies will continue as planned over the course
of the current financial year 2016.

CEO Dr. Mariola Söhngen: "We are very satisfied with business performance
in 2015. With its broad range of applications, its ability to activate the
immune system and excellent tolerability, our lead product lefitolimod is
an extraordinary product with blockbuster potential within the growing
market of immunotherapies. Our primary objective is therefore to make
lefitolimod market ready in cancer, explore its potential in HIV further
and exploit the potential of our rich pipeline."

Significant progress and broadening of the studies involving the lead
product lefitolimod
The most advanced product in the MOLOGEN pipeline, MGN1703, has been
officially listed by the World Health Organization since January 2016 and
has therefore also been granted an international nonproprietary name:
"lefitolimod". In addition to the indications colorectal cancer and small
cell lung cancer, the immunotherapy has also been used to treat HIV